CorMedix (CRMD) Stock Rating Reaffirmed by Roth Capital
CorMedix (NASDAQ:CRMD)‘s stock had its “buy” rating reissued by research analysts at Roth Capital in a research note issued to investors on Thursday. They presently have a $6.00 price target on the stock. Roth Capital’s price objective would suggest a potential upside of 270.37% from the stock’s current price.
Shares of CRMD stock traded down $0.03 on Thursday, reaching $1.62. 6,964,858 shares of the company’s stock traded hands.
CorMedix (NASDAQ:CRMD) last issued its quarterly earnings results on Wednesday, November 14th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $0.05 million.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Featured Story: What are the reasons investors use put options?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.